Regeneron Pharmaceuticals, Inc. vs Pfizer, Inc. — Stock Comparison

REGN
Regeneron Pharmaceuticals, Inc.
$704.56
▲ 2.65%
vs
PFE
Pfizer, Inc.
$26.69
▲ 1.62%
Q·Score Winner
Regeneron Pharmaceuticals, Inc.
REGN8/10vs 6.5/10

Q·Score Breakdown

8
Buy
Overall
6.5
Hold
8.2
Quality
7.4
9.7
Health
7
7.3
Growth
5.6
7.2
Valuation
6.7
7.7
Sentiment
5.2
REGN

Clean balance sheet with low leverage (0.1× debt-to-equity).

PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

Analyst Consensus

BUY
Target $877.73 (+24.6%)
28 analysts
HOLD
Target $29.00 (+8.7%)
27 analysts

Fundamentals

REGN
PFE
17.2×
Trailing P/E
19.6×
13.3×
Forward P/E
9.5×
29.6%
Profit Margin
12.4%
44.6%
Gross Margin
75.8%
14.5%
ROE
8.9%
19.0%
Revenue Growth
-1.2%
-7.2%
Earnings Growth
0.40
Beta
0.39
Price / Book
$73.9B
Market Cap
$151.8B
$476 – $821
52-Week Range
$22 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.